Terms: = Liver cancer AND IDH2, P48735, 3418, ENSG00000182054, IDHM, mNADP-IDH, IDH, IDP, ICD-M AND Diagnosis
12 results:
1. REGOMA-OSS: a large, Italian, multicenter, prospective, observational study evaluating the efficacy and safety of regorafenib in patients with recurrent glioblastoma.
Caccese M; Desideri I; Villani V; Simonelli M; Buglione M; Chiesa S; Franceschi E; Gaviani P; Stasi I; Caserta C; Brugnara S; Lolli I; Bennicelli E; Bini P; Cuccu AS; Scoccianti S; Padovan M; Gori S; Bonetti A; Giordano P; Pellerino A; Gregucci F; Riva N; Cinieri S; Internò V; Santoni M; Pernice G; Dealis C; Stievano L; Paiar F; Magni G; De Salvo GL; Zagonel V; Lombardi G
ESMO Open; 2024 Apr; 9(4):102943. PubMed ID: 38492275
[TBL] [Abstract] [Full Text] [Related]
2. idh-negative chondrosarcoma with metachronous dedifferentiation only in the metastatic site-A diagnostic pitfall.
Sekita T; Yoshida A; Kawai A; Ichikawa H; Kobayashi E
Genes Chromosomes Cancer; 2023 Dec; 62(12):755-760. PubMed ID: 37732625
[TBL] [Abstract] [Full Text] [Related]
3. New Options for Systemic Therapies in Intrahepatic Cholangiocarcinoma (iCCA).
Becht R; Wasilewicz MP
Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374378
[TBL] [Abstract] [Full Text] [Related]
4. Intrahepatic cholangiocarcinoma: Tumour heterogeneity and its clinical relevance.
Komuta M
Clin Mol Hepatol; 2022 Jul; 28(3):396-407. PubMed ID: 35032970
[TBL] [Abstract] [Full Text] [Related]
5. idh Mutation Subgroup Status Associates with Intratumor Heterogeneity and the Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.
Xiang X; Liu Z; Zhang C; Li Z; Gao J; Zhang C; Cao Q; Cheng J; Liu H; Chen D; Cheng Q; Zhang N; Xue R; Bai F; Zhu J
Adv Sci (Weinh); 2021 Sep; 8(17):e2101230. PubMed ID: 34250753
[TBL] [Abstract] [Full Text] [Related]
6. Diagnostic accuracy of liver Imaging Reporting and Data System locoregional treatment response criteria: a systematic review and meta-analysis.
Gupta P; Bansal A; Das GC; Kumar-M P; Chaluvashetty SB; Bhujade H; Gulati A; Kalra N
Eur Radiol; 2021 Oct; 31(10):7725-7733. PubMed ID: 33786656
[TBL] [Abstract] [Full Text] [Related]
7. [Personalized treatment of cholangiocellular carcinoma (CCA)].
Jödicke L; Zender L; Malek NP
Internist (Berl); 2020 Feb; 61(2):170-174. PubMed ID: 31938815
[TBL] [Abstract] [Full Text] [Related]
8. Immunomorphology and molecular biology of mixed primary liver cancers: is Nestin a marker of intermediate-cell carcinoma?
Malvi D; de Biase D; Fittipaldi S; Grillini M; Visani M; Pession A; D'Errico A; Vasuri F
Histopathology; 2020 Jan; 76(2):265-274. PubMed ID: 31374137
[TBL] [Abstract] [Full Text] [Related]
9. A Case of Metastatic Biliary Tract cancer Diagnosed Through Identification of an
Kamath SD; Lin X; Kalyan A
Oncologist; 2019 Feb; 24(2):151-156. PubMed ID: 30352944
[TBL] [Abstract] [Full Text] [Related]
10. Genomic and transcriptional alterations of cholangiocarcinoma.
Ito T; Sakurai-Yageta M; Goto A; Pairojkul C; Yongvanit P; Murakami Y
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):380-7. PubMed ID: 24532422
[TBL] [Abstract] [Full Text] [Related]
11. Pathogenesis, diagnosis, and management of cholangiocarcinoma.
Rizvi S; Gores GJ
Gastroenterology; 2013 Dec; 145(6):1215-29. PubMed ID: 24140396
[TBL] [Abstract] [Full Text] [Related]
12. Visceral lesions occurring during follow-up of melanoma patients: a true place for other diagnosis than melanoma metastasis.
Battistella M; Robert C; Gossot D; Dupuy A; Mateus C; Kérob D; Avril MF; Basset-Seguin N; Lebbé C; de Kerviler E; Viguier M
J Eur Acad Dermatol Venereol; 2012 May; 26(5):602-10. PubMed ID: 21615526
[TBL] [Abstract] [Full Text] [Related]
